Implantable cardioverter- de brillator ef cacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population). Am J Cardiol 2005;95: 1487 91. 271. Mozaffarian D, Anker SD, Anand I, et al. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation 2007;116: 392 8. 272. Rickard J, Bassiouny M, Cronin EM, et al. Predictors of response to cardiac resynchronization therapy in patients with a non-left bundle branch block morphology. Am J Cardiol 2011;108:1576 80. 273. Deleted in press. 274. Russell SD, Miller LW, Pagani FD. Advanced heart failure: a call to action. Congest Heart Fail 2008;14:316 21. 275. Aranda JM Jr., Scho eld RS, Pauly DF, et al. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac trans- plantation: a prospective, randomized trial. Am Heart J 2003;145:324 9. 276. Brozena SC, Twomey C, Goldberg LR, et al. A prospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at home. J Heart Lung Transplant 2004;23: 1082 6. 277. Cuffe MS, Califf RM, Adams KF Jr., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287:1541 7. 278. Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J 2007;153:98 104. 279. Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005;46:57 64. 280. O Connor CM, Gattis WA, Uretsky BF, et al. 